Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
Launched by CHINESE UNIVERSITY OF HONG KONG · Sep 13, 2019
Trial Information
Current as of September 12, 2025
Completed
Keywords
ClinConnect Summary
A Chinese treatment protocol would be developed based on the UP-A. The adolescent program consists of 8 modules, and the parent program consists of 3 modules. Similar to the work by Ehrenreich and Barlow, a flexible modular approach would be adopted, when extra sessions would be arranged to cater for individual treatment needs and heterogeneity of symptom severity. The whole treatment comprised of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardian. The total duration would be around 3 months. Each treatment sessions would be around 1 hour.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 13 to 18 years.
- • Primary diagnosis of any depression and/or anxiety disorders in fifth edition of the Diagnostic and Statistical Manual
- • Use Chinese as primary written language
- • For adolescents on medication, there must be 6-week stabilization period before study entry
- Exclusion Criteria:
- • Diagnoses of psychotic disorders, organic brain disease, bipolar disorder
- • In high risk of self-harm or suicide
- • Significant cognitive impairment (intellectual quotient lower than 80)
- • Autism Spectrum Disorders
- • Externalizing disorders with serious treatment interfering disruptive behavioural problems or substance abuse
- • Attending concurrent psychotherapy
- • Experience of attending a full-course of cognitive behavior therapy for anxiety or depression
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hk, Hong Kong
Patients applied
Trial Officials
Sophie Yan Yan Cheung, MSocSc
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials